NASDAQ:CGON CG Oncology (CGON) Stock Price, News & Analysis $38.05 +0.49 (+1.30%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$37.37▼$39.0350-Day Range$30.78▼$38.2052-Week Range$25.77▼$50.23Volume798,507 shsAverage Volume634,532 shsMarket Capitalization$2.54 billionP/E RatioN/ADividend YieldN/APrice Target$64.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get CG Oncology alerts: Email Address CG Oncology MarketRank™ Stock AnalysisAnalyst RatingBuy3.14 Rating ScoreUpside/Downside68.6% Upside$64.17 Price TargetShort InterestBearish17.72% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.85Based on 4 Articles This WeekInsider TradingSelling Shares$23 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.47) to ($1.91) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.82 out of 5 starsMedical Sector832nd out of 910 stocksBiological Products, Except Diagnostic Industry145th out of 155 stocks 3.6 Analyst's Opinion Consensus RatingCG Oncology has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCG Oncology has only been the subject of 3 research reports in the past 90 days.Read more about CG Oncology's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted17.72% of the float of CG Oncology has been sold short.Short Interest Ratio / Days to CoverCG Oncology has a short interest ratio ("days to cover") of 11.7, which indicates bearish sentiment.Change versus previous monthShort interest in CG Oncology has recently increased by 2.05%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCG Oncology does not currently pay a dividend.Dividend GrowthCG Oncology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CGON. Previous Next 2.7 News and Social Media Coverage News SentimentCG Oncology has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for CG Oncology this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for CGON on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added CG Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CG Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $23,000,089.00 in company stock.Percentage Held by InstitutionsOnly 26.56% of the stock of CG Oncology is held by institutions.Read more about CG Oncology's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for CG Oncology are expected to decrease in the coming year, from ($1.47) to ($1.91) per share.Price to Book Value per Share RatioCG Oncology has a P/B Ratio of 4.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about CG Oncology's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Sasco Gold LLCSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." I believe the American people deserve to control the fate of their own life savings which is why I had my team put together our latest guide to protect your hard-earned wealth before it's too late... [RUSH MY FREE GUIDE] About CG Oncology Stock (NASDAQ:CGON)CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.Read More CGON Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CGON Stock News HeadlinesAugust 31, 2024 | insidertrades.comCG Oncology, Inc. (NASDAQ:CGON) Director Hong Fang Song Sells 650,455 SharesSeptember 2, 2024 | americanbankingnews.comCG Oncology, Inc. (NASDAQ:CGON) Director Sells $23,000,088.80 in StockSeptember 7, 2024 | Weiss Ratings (Ad)What is Nvidia’s New $1 Trillion SuperProject?Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …September 1, 2024 | americanbankingnews.comCG Oncology, Inc. (NASDAQ:CGON) Receives $64.00 Consensus Price Target from AnalystsSeptember 1, 2024 | americanbankingnews.comContrasting CG Oncology (NASDAQ:CGON) & Revolution Medicines (NASDAQ:RVMD)August 31, 2024 | americanbankingnews.comCG Oncology, Inc. (NASDAQ:CGON) Forecasted to Post Q3 2024 Earnings of ($0.43) Per ShareAugust 30, 2024 | globenewswire.comCG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceAugust 29, 2024 | msn.comRoth MKM Initiates Coverage of CG Oncology (CGON) with Buy RecommendationSeptember 7, 2024 | Weiss Ratings (Ad)What is Nvidia’s New $1 Trillion SuperProject?Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …August 29, 2024 | americanbankingnews.comCG Oncology (NASDAQ:CGON) Upgraded at Roth CapitalAugust 29, 2024 | americanbankingnews.comCG Oncology (NASDAQ:CGON) Upgraded to "Strong-Buy" by Roth CapitalAugust 29, 2024 | americanbankingnews.comCG Oncology (NASDAQ:CGON) Research Coverage Started at Roth MkmAugust 28, 2024 | msn.comRoth starts CG Oncology at buy, cites anticipated FDA filingAugust 21, 2024 | finance.yahoo.comBullish CG Oncology Insiders Loaded Up On US$5.06m Of StockAugust 10, 2024 | markets.businessinsider.comBuy Rating for CG Oncology: Promising CG0070 Data Signals Strong Market PotentialAugust 8, 2024 | finanznachrichten.deCG Oncology Inc.: CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business UpdatesAugust 8, 2024 | globenewswire.comCG Oncology Reports Second Quarter 2024 Financial Results and Provides Business UpdatesJuly 25, 2024 | finance.yahoo.comInstitutional investors in CG Oncology, Inc. (NASDAQ:CGON) must be dismayed after prices dropped by 13% last weekSee More Headlines Receive CGON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CG Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CGON Previous SymbolNASDAQ:CGON CUSIPN/A CIK1991792 Webcgoncology.com Phone949-419-6203FaxN/AEmployees61Year FoundedN/APrice Target and Rating Average Stock Price Target$64.17 High Stock Price Target$75.00 Low Stock Price Target$50.00 Potential Upside/Downside+68.6%Consensus RatingBuy Rating Score (0-4)3.14 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio47.57 Quick Ratio47.57 Sales & Book Value Annual Sales$650,000.00 Price / Sales3,901.00 Cash FlowN/A Price / Cash FlowN/A Book Value$8.23 per share Price / Book4.62Miscellaneous Outstanding Shares66,640,000Free FloatN/AMarket Cap$2.54 billion OptionableOptionable BetaN/A Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Arthur Kuan (Age 33)Chairman & CEO Comp: $640.97kMr. Ambaw Bellete M.S. (Age 53)President & COO Comp: $1.06MDr. Vijay Kasturi M.D. (Age 56)Chief Medical Officer Comp: $212.24kMs. Corleen M. Roche (Age 57)CFO & Secretary Ms. Amy SteeleVice President of Finance, Accounting & AdministrationMr. Swapnil Bhargava Ph.D.Chief Technical OfficerMr. Bing KungVice President of Corporate DevelopmentMore ExecutivesKey CompetitorsSummit TherapeuticsNASDAQ:SMMTRoivant SciencesNASDAQ:ROIVIntra-Cellular TherapiesNASDAQ:ITCIElanco Animal HealthNYSE:ELANLantheusNASDAQ:LNTHView All CompetitorsInsiders & InstitutionsHong Fang SongSold 650,455 sharesTotal: $23.00 M ($35.36/share)Point72 Asset Management L.P.Sold 75,827 shares on 8/19/2024Ownership: 0.166%Perceptive Advisors LLCSold 570,410 shares on 8/16/2024Ownership: 1.101%Driehaus Capital Management LLCSold 1,006 shares on 8/16/2024Ownership: 0.160%The Manufacturers Life Insurance Company Sold 3,473 shares on 8/15/2024Ownership: 0.090%View All Insider TransactionsView All Institutional Transactions CGON Stock Analysis - Frequently Asked Questions How have CGON shares performed this year? CG Oncology's stock was trading at $37.17 at the beginning of the year. Since then, CGON shares have increased by 2.4% and is now trading at $38.05. View the best growth stocks for 2024 here. How were CG Oncology's earnings last quarter? CG Oncology, Inc. (NASDAQ:CGON) issued its quarterly earnings results on Thursday, August, 8th. The company reported ($0.28) earnings per share for the quarter, beating analysts' consensus estimates of ($0.42) by $0.14. The company had revenue of $0.11 million for the quarter. When did CG Oncology IPO? CG Oncology (CGON) raised $380 million in an IPO on Thursday, January 25th 2024. The company issued 20,000,000 shares at $19.00 per share. When did the company's lock-up period expire? CG Oncology's lock-up period expired on Tuesday, July 23rd. CG Oncology had issued 20,000,000 shares in its public offering on January 25th. The total size of the offering was $380,000,000 based on an initial share price of $19.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the expiration of the lock-up period. Who are CG Oncology's major shareholders? Top institutional investors of CG Oncology include Yu Fan (2.37%), Perceptive Advisors LLC (1.10%), Deerfield Management Company L.P. Series C (0.65%) and Massachusetts Financial Services Co. MA (0.40%). Insiders that own company stock include Hong Fang Song, Decheng Capital Global Life Sc, Corleen M Roche and Vijay Kasturi. View institutional ownership trends. How do I buy shares of CG Oncology? Shares of CGON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CGON) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CG Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CG Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
